ImmuCell Corporation (ICCC)

$8.25

-0.29 (-3.40%)
Rating:
Recommendation:
Buy
Symbol ICCC
Price $8.25
Beta 0.682
Volume Avg. 0.01M
Market Cap 63.879M
Shares () -
52 Week Range 7.3-10.96
1y Target Est -
DCF Unlevered ICCC DCF ->
DCF Levered ICCC LDCF ->
ROE 3.36% Neutral
ROA 2.35% Neutral
Operating Margin -
Debt / Equity 39.93% Neutral
P/E 58.93 Strong Buy
P/B 1.91 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ICCC news


Mr. Michael Brigham
Healthcare
Biotechnology
NASDAQ Capital Market

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.